Tectonic Operating Company

Tectonic Therapeutic is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapies targeting G-protein coupled receptors (GPCRs). Utilizing its proprietary GEOD (GPCR Ensemble Orphan Drug) platform, the company overcomes traditional challenges in GPCR drug discovery to create biologics for receptors that have been difficult to target with small molecules. Its lead program, TX000045, is a long-acting Fc-relaxin fusion protein targeting the RXFP1 receptor for the treatment of heart failure with preserved ejection fraction (HFpEF). Tectonic aims to address significant unmet medical needs in cardiovascular and fibrotic diseases through its innovative pipeline of GPCR-targeted biologics. The company transitioned to the public markets in 2024 via a merger with AVROBIO and continues to advance its platform toward multiple therapeutic indications.